BioCentury | Apr 15, 2021
Regulation

Downsized FerGene gains FDA extension to resubmit gene therapy, resolve CMC issues

A year after Blackstone-backed Ferring subsidiary FerGene received a complete response letter for its gene therapy for bladder cancer, investors in the downsized biotech remain committed to the project as it plans to resubmit its...
BioCentury | Apr 15, 2021
Deals

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

A deal with I-Mab is one of what Genechem hopes will be many to leverage an antibody discovery platform that it’s been building for the past five years. Shanghai Genechem Co. Ltd. and I-Mab...
BioCentury | Apr 14, 2021
Deals

April 13 Quick Takes: Mega-rounds for Flagship's Repertoire, Arcellx, GH, Theseus; plus Biophytis, Resilience, Cerevel, C4X, Sanofi and more

Immune medicines company Repertoire Immune Medicines Inc. raised $189 million in a series B financing from founding investor Flagship Pioneering and other investors including Softbank Vision Fund 2i, the Public Sector Pension Investment Board (PSP...
BioCentury | Apr 14, 2021
Management Tracks

CEO succession at Amarin; plus Lilly, IGM, Jounce and more

John Thero will retire as president, CEO and board member at Amarin Corp. plc (NASDAQ:AMRN) on August 1. Thero will be replaced by Karim Mikhail,  SVP and head of commercial for Europe at the cardiovascular...
BioCentury | Apr 14, 2021
Emerging Company Profile

Jaguar to deploy $139M series B toward broad gene therapy pipeline

Less than two months after emerging from stealth, Jaguar raised a $139 million series B co-led by Lilly and Deerfield that will further facilitate translation of its executives’ experience developing SMA...
BioCentury | Apr 13, 2021
Deals

April 12 Quick Takes: DiaSorin buying Luminex for $1.8B; plus Antios, Reneo, VectivBio, Pulmatrix, Taysha

DiaSorin S.p.A. (MTAA:DIA) is acquiring multiplexing technology company Luminex Corp. (NASDAQ:LMNX) for $1.8 billion in a deal that expands the Italian in vitro diagnostic company’s footprint in the U.S. and its molecular diagnostics portfolio. The combined...
BioCentury | Apr 13, 2021
Deals

Sanofi joins in vivo cell engineering wave, snapping up stealthy Fred Hutch mRNA delivery spinout

Acquired by Sanofi before making its official debut, Tidal is the latest example of a vector-focused company enabling democratization of immune cell therapies via in vivo engineering.  Shareholders of the Fred Hutchinson Cancer Research Center...
BioCentury | Apr 10, 2021
Product Development

Bispecific constructs move beyond T cell engagers at AACR

T cell engagers have dominated the bispecific antibody scene for the past five years, but the industry is starting to branch out into next-generation structures that offer new functions and potential improvements over first-generation compounds. ...
BioCentury | Apr 9, 2021
Management Tracks

Bryce joins Rain as CMO; plus Ichnos, Dementia Discovery Fund, Akoya and more

Richard Bryce joined precision oncology company Rain Therapeutics Inc. as EVP and CMO. Most recently, Bryce was chief medical and scientific officer at Puma Biotechnology Inc. (NASDAQ:PBYI). Oncology and autoimmune company Ichnos Sciences Inc. hired...
BioCentury | Apr 9, 2021
Translation in Brief

Two ways to reverse CAR T cell exhaustion; plus a ligand and its receptor in a single vector, Cleave, Amazentis and Cello

A Stanford University team led by Crystal Mackall, co-founder of Lyell Immunopharma Inc. and Obsidian Therapeutics Inc., described in Science two ways to prevent or reverse CAR T cell exhaustion. The first is based on a...
Items per page:
1 - 10 of 22683
BioCentury | Apr 15, 2021
Regulation

Downsized FerGene gains FDA extension to resubmit gene therapy, resolve CMC issues

A year after Blackstone-backed Ferring subsidiary FerGene received a complete response letter for its gene therapy for bladder cancer, investors in the downsized biotech remain committed to the project as it plans to resubmit its...
BioCentury | Apr 15, 2021
Deals

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

A deal with I-Mab is one of what Genechem hopes will be many to leverage an antibody discovery platform that it’s been building for the past five years. Shanghai Genechem Co. Ltd. and I-Mab...
BioCentury | Apr 14, 2021
Deals

April 13 Quick Takes: Mega-rounds for Flagship's Repertoire, Arcellx, GH, Theseus; plus Biophytis, Resilience, Cerevel, C4X, Sanofi and more

Immune medicines company Repertoire Immune Medicines Inc. raised $189 million in a series B financing from founding investor Flagship Pioneering and other investors including Softbank Vision Fund 2i, the Public Sector Pension Investment Board (PSP...
BioCentury | Apr 14, 2021
Management Tracks

CEO succession at Amarin; plus Lilly, IGM, Jounce and more

John Thero will retire as president, CEO and board member at Amarin Corp. plc (NASDAQ:AMRN) on August 1. Thero will be replaced by Karim Mikhail,  SVP and head of commercial for Europe at the cardiovascular...
BioCentury | Apr 14, 2021
Emerging Company Profile

Jaguar to deploy $139M series B toward broad gene therapy pipeline

Less than two months after emerging from stealth, Jaguar raised a $139 million series B co-led by Lilly and Deerfield that will further facilitate translation of its executives’ experience developing SMA...
BioCentury | Apr 13, 2021
Deals

April 12 Quick Takes: DiaSorin buying Luminex for $1.8B; plus Antios, Reneo, VectivBio, Pulmatrix, Taysha

DiaSorin S.p.A. (MTAA:DIA) is acquiring multiplexing technology company Luminex Corp. (NASDAQ:LMNX) for $1.8 billion in a deal that expands the Italian in vitro diagnostic company’s footprint in the U.S. and its molecular diagnostics portfolio. The combined...
BioCentury | Apr 13, 2021
Deals

Sanofi joins in vivo cell engineering wave, snapping up stealthy Fred Hutch mRNA delivery spinout

Acquired by Sanofi before making its official debut, Tidal is the latest example of a vector-focused company enabling democratization of immune cell therapies via in vivo engineering.  Shareholders of the Fred Hutchinson Cancer Research Center...
BioCentury | Apr 10, 2021
Product Development

Bispecific constructs move beyond T cell engagers at AACR

T cell engagers have dominated the bispecific antibody scene for the past five years, but the industry is starting to branch out into next-generation structures that offer new functions and potential improvements over first-generation compounds. ...
BioCentury | Apr 9, 2021
Management Tracks

Bryce joins Rain as CMO; plus Ichnos, Dementia Discovery Fund, Akoya and more

Richard Bryce joined precision oncology company Rain Therapeutics Inc. as EVP and CMO. Most recently, Bryce was chief medical and scientific officer at Puma Biotechnology Inc. (NASDAQ:PBYI). Oncology and autoimmune company Ichnos Sciences Inc. hired...
BioCentury | Apr 9, 2021
Translation in Brief

Two ways to reverse CAR T cell exhaustion; plus a ligand and its receptor in a single vector, Cleave, Amazentis and Cello

A Stanford University team led by Crystal Mackall, co-founder of Lyell Immunopharma Inc. and Obsidian Therapeutics Inc., described in Science two ways to prevent or reverse CAR T cell exhaustion. The first is based on a...
Items per page:
1 - 10 of 22683